According to Zacks, “Jaguar Animal Health, Inc. is an animal health company. The company is engaged in developing and commercializing gastrointestinal products for companion and production animals. Its pipeline of prescription drug product includes Canalevia(TM), species-specific formulations of crofelemer, Virend and species-specific formulations of NP-500. The Company’s non-prescription products comprises of Neonorm(TM) Calf and species-specific formulations of Neonorm. Jaguar Animal Health, Inc. is headquartered in San Francisco, California. “
Shares of Jaguar Animal Health (NASDAQ:JAGX) traded up 3.9219% on Tuesday, reaching $0.6651. The company had a trading volume of 251,333 shares. The company’s 50-day moving average is $0.71 and its 200-day moving average is $1.20. The company’s market capitalization is $8.21 million. Jaguar Animal Health has a one year low of $0.61 and a one year high of $4.60.
About Jaguar Animal Health
Jaguar Animal Health, Inc is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a formulation of a Croton lechleri product for the treatment of ulcers in horses. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products.
Receive News & Ratings for Jaguar Animal Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.